KYNTRA BIO, INC.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
KYNB$3.57-8.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a) We have filed the following documents as part of this Annual Report:
- Consolidated Financial Statements
Information in response to this Item is included in Part II, Item 8 of this Annual Report.
- Financial Statement Schedules
Schedule II is included on page 136. All other schedules are omitted because they are not required or the required information is included in the consolidated financial statements or notes thereto.
- Exhibits
See Item 15(b) below.
(b)Exhibits—We have filed, or incorporated into this Annual Report by reference, the exhibits listed below. Where an exhibit is incorporated by reference, the number in parentheses indicates the document to which cross-reference is made. Refer to the end of this table for a listing of cross-reference documents.
| Exhibit · Incorporation By Reference | |||||
|---|---|---|---|---|---|
| Number | Exhibit Description | Form | SEC File No. | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation of FibroGen, Inc. | 8-K | 001-36740 | 3.1 | 11/21/2014 |
| 3.2 | Amended and Restated Bylaws of FibroGen, Inc. | S-1/A | 333-199069 | 3.4 | 10/23/2014 |
| 4.1 | Form of Common Stock Certificate. | 8-K | 001-36740 | 4.1 | 11/21/2014 |
| 4.2 | Shareholders’ Agreement by and among FibroGen International (Cayman) Limited and certain of its shareholders, dated as of September 8, 2017. | 10-Q | 001-36740 | 4.6 | 11/8/2017 |
| 4.3 | Common Stock Purchase Agreement by and between FibroGen, Inc. and AstraZeneca AB, dated as of October 20, 2014. | S-1/A | 333-199069 | 4.17 | 10/24/2014 |
| 4.4 | Description of Capital Stock of FibroGen, Inc. | 10-K | 001-36740 | 4.4 | 3/2/2020 |
| 10.1+ | FibroGen, Inc. 2024 Equity Incentive Plan. | 8-K | 001-36740 | 10.1 | 6/7/2024 |
| 10.1(ii)+ | Form of Restricted Stock Unit Grant Notice and Award Agreement. | 10-Q | 001-36740 | 10.4 | 8/6/2024 |
| 10.1(iii)+ | Form of Stock Option Grant Notice and Option Agreement. | 10-Q | 001-36740 | 10.5 | 8/6/2024 |
| 10.2+ | FibroGen, Inc. 2014 Equity Incentive Plan and forms of agreement thereunder. | S-1/A | 333-199069 | 10.4 | 11/12/2014 |
| 10.3+ | FibroGen, Inc. 2014 Employee Stock Purchase Plan. | S-1/A | 333-199069 | 10.5 | 11/12/2014 |
| 10.4+ | FibroGen, Inc. Non-Employee Director Compensation Policy, as amended, dated April 22, 2024. | 10-Q | 001-36740 | 10.3 | 5/6/2024 |
| 10.5*+ | FibroGen, Inc. Bonus Plan. | — | — | — | — |
| 10.6* | FibroGen Insider Trading and Trading Window Policy, amended and restated as of November 2021. | — | — | — | — |
| 10.7 | Lease for Premises in Beijing BDA Biomedical Park by and among Beijing FibroGen Medical Technology Development Co., Ltd., Beijing Economic and Technology Investment Development Parent Company and Beijing BDA International Biological Pharmaceutical Investment Management Co., Ltd., effective as of February 1, 2013, as supplemented by the Supplementary Agreement to Lease of Premises in Beijing BDA Biomedical Park by and among Beijing FibroGen Medical Technology Development Co., Ltd., Beijing Economic Technology Investment Development Parent Company and Beijing BDA International Biological Pharmaceutical Investment Management Co., Ltd., dated as of January 30, 2013. | S-1 | 333-199069 | 10.9 | 10/1/2014 |
| 10.8+ | Form of Employment Offer Letter. | S-1 | 333-199069 | 10.10 | 10/1/2014 |
| 10.9† | Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of June 1, 2005. | 10-Q | 001-36740 | 10.1 | 11/5/2020 |
| 10.9(i)† | Amendment No. 1 to Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of January 1, 2013. | 10-K | 001-36740 | 10.9(i) | 2/27/2019 |
| 10.10† | Anemia License and Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of April 28, 2006. | S-1 | 333-199069 | 10.12 | 10/1/2014 |
| 10.11† | Amendment to Anemia License and Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of August 31, 2006. | S-1 | 333-199069 | 10.13 | 10/1/2014 |
| 10.12 | Amendment No. 2 to Anemia License and Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of December 1, 2006. | S-1 | 333-199069 | 10.14 | 10/1/2014 |
| 10.13† | Supplement to Anemia License and Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., effective as of April 28, 2006. | S-1 | 333-199069 | 10.15 | 10/1/2014 |
| 10.14† | Amendment No. 3 to Anemia License and Collaboration Agreement, by and between FibroGen, Inc. and Astellas Pharma Inc., dated as of May 10, 2012. | S-1 | 333-199069 | 10.16 | 10/1/2014 |
| 10.15+ | Form of Indemnity Agreement by and between FibroGen, Inc. and its directors and officers. | S-1/A | 333-199069 | 10.27 | 10/23/2014 |
| 10.16† | Commercial Supply Agreement by and between FibroGen, Inc. and Catalent Pharma Solutions, LLC, effective as of January 1, 2020. | 10-K | 001-36740 | 10.28 | 3/2/2020 |
| 10.17† | Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd. and STA Pharmaceutical Hong Kong Limited, effective March 2, 2020. | 8-K | 001-36740 | 99.1 | 3/24/2020 |
| 10.18† | Amendment No.1 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd. and STA Pharmaceutical Hong Kong Limited, effective May 11, 2020. | 10-Q | 001-36740 | 10.2 | 8/6/2020 |
| 10.19† | Second Amended and Restated License, Development and Commercialization Agreement by and among FibroGen China Anemia Holdings, Ltd., FibroGen China Medical Technology Development Co., Ltd., FibroGen International (Hong Kong) Limited, and AstraZeneca AB, effective July 1, 2020. | 10-Q | 001-36740 | 10.3 | 8/6/2020 |
| 10.20† | Amendment No. 2 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd. and STA Pharmaceutical Hong Kong Limited, effective July 24, 2020. | 10-Q | 001-36740 | 10.8 | 11/5/2020 |
| 10.21† | Astellas EU Supply Agreement by and between FibroGen, Inc. and Astellas Pharma Europe Ltd, effective as of January 1, 2021. | 10-Q | 001-36740 | 10.2 | 5/10/2021 |
| 10.22† | Amendment No. 3 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd., and STA Pharmaceutical Hong Kong Limited, dated as of January 12, 2021. | 10-Q | 001-36740 | 10.3 | 5/10/2021 |
| 10.23† | Exclusive License and Option Agreement by and between FibroGen, Inc. and HiFiBiO (HK) Limited (D.B.A. HiFiBiO Therapeutics), dated as of June 16, 2021. | 10-Q | 001-36740 | 10.2 | 8/9/2021 |
| 10.24† | Amendment No. 4 to Master Supply Agreement by and among FibroGen, Inc., Shanghai SynTheAll Pharmaceutical Co., Ltd., and STA Pharmaceutical Hong Kong Limited, dated as of October 29, 2021. | 10-K | 001-36740 | 10.36 | 2/28/2022 |
| 10.25+ | Offer Letter, by and between FibroGen, Inc. and Christine Chung, dated as of June 17, 2008. | 10-K | 001-36740 | 10.32 | 3/2/2020 |
| 10.26† | Amendment No.1 to the Exclusive License and Option Agreement, between HiFiBiO Inc. and FibroGen, Inc., dated February 14, 2024. | 10-Q | 001-36740 | 10.1 | 5/6/2024 |
| 10.27+ | Form of Executive Officer Change in Control and Severance Agreement. | 10-K | 001-36740 | 10.35 | 3/2/2020 |
| 10.28 | ATM Equity Offering Sales Agreement, by and between FibroGen, Inc. and BofA Securities, Inc., dated as of February 24, 2025. | 8-K | 001-36740 | 1.1 | 2/24/2025 |
| 10.29† | Revenue Interest Financing Agreement by and between FibroGen, Inc. and NQ Project Phoebus, L.P., dated as of November 4, 2022. | 10-K | 001-36740 | 10.46 | 2/27/2023 |
| 10.30† | Letter Agreement by and among Astellas Pharma Inc., Astellas Pharma Europe Ltd., and FibroGen, Inc., effective as of November 4, 2022. | 10-K | 001-36740 | 10.47 | 2/27/2023 |
| 10.31† | Amendment No.1 to Commercial Supply Agreement (Roxadustat) by and between FibroGen, Inc. and its Affiliates and Catalent Pharma Solutions, LLC, effective as of January 1, 2023. | 10-Q | 001-36740 | 10.2 | 5/8/2023 |
| 10.32+ | Form of Executive Officer Change in Control and Severance Agreement. | 10-Q | 001-36740 | 10.4 | 5/8/2023 |
| 10.33+ | Offer Letter, dated July 23, 2023, between FibroGen, Inc. and Thane Wettig. | 8-K | 001-36740 | 10.1 | 7/25/2023 |
| 10.34† | Amended and Restated Exclusive License Agreement by and among FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd., and Eluminex Biosciences (Suzhou) Limited, dated April 19, 2023. | 10-Q | 001-36740 | 10.4 | 8/7/2023 |
| 10.35† | Financing Agreement by and among FibroGen, Inc., certain of its subsidiaries, NHTV Fairview Holding LLC, NHTV II Fairview Holding LLC, MSTV Fund II Employees Fairview Holding LLC, and Wilmington Trust, National Association, dated as of April 29, 2023. | 10-Q | 001-36740 | 10.5 | 8/7/2023 |
| 10.36† | First Amended and Restated Evaluation Agreement by and between FibroGen, Inc. and Fortis Therapeutics, Inc., dated June 6, 2024. | 10-Q | 001-36740 | 10.2 | 8/6/2024 |
| 10.37† | First Amended and Restated Option Agreement and Plan of Merger by and among FibroGen, Inc., Fortis Therapeutics, Inc., and Shareholder Representative Services LLC, dated June 6, 2024. | 10-Q | 001-36740 | 10.3 | 8/6/2024 |
| 10.38† | Amendment No. 1 to the Second Amended and Restated Exclusive License Agreement, by and between FibroGen (China) Medical Technology Development Co., Ltd. and Eluminex Biosciences (Suzhou) Limited, dated as of November 16, 2023. | 10-K | 001-36740 | 10.53 | 2/26/2024 |
| 10.39† | Termination and Transition Agreement to Development and Commercialization Agreement (for the U.S. and Certain Other Territories), by and between AstraZeneca AB and FibroGen, Inc., dated February 25, 2024. | 10-Q | 001-36740 | 10.2 | 5/6/2024 |
| 21.1 | Subsidiaries of FibroGen, Inc. | 10-Q | 001-36740 | 21.1 | 8/9/2021 |
| 23.1* | Consent of PricewaterhouseCoopers LLP. | — | — | — | — |
| 24.1* | Power of Attorney (included in signature pages). | — | — | — | — |
| 31.1* | Certification of Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a). | — | — | — | — |
| 31.2* | Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a). | — | — | — | — |
| 32.1** | Certification of Principal Executive Officer and Principal Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)(1). | — | — | — | — |
| 97.1 | Policy for Recoupment of Incentive Compensation. | 10-K | 001-36740 | 97.1 | 2/26/2024 |
| 101.INS* | Inline XBRL Instance Document: the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | — | — | — | — |
| 101.SCH* | Inline XBRL Taxonomy Schema Linkbase Document | — | — | — | — |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | — | — | — | — |
- Filed herewith.
** Furnished herewith.
† Portions of this exhibit (indicated by asterisks) have been omitted as the Company has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm if publicly disclosed or is the type of information the Company treats as confidential.
- Indicates a management contract or compensatory plan.
(1)
This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of FibroGen, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
(c)Financial Statement Schedules—See (a) 2 above. All other financial statement schedules are omitted because they are not applicable because the requested information is included in the consolidated financial statements or notes thereto.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.